Magnelek

General characteristics. Structure:

Active ingredient: 100 mg of magnesium (in an equivalent to magnesium to citrate of 618,4 mg), 10 mg of a pyridoxine of a hydrochloride.

Excipients: anhydrous citric acid, sugar.

The combined medicine containing magnesium and B6 vitamin in optimum quantities.

Pharmacological properties:

Pharmacodynamics. Magnesium is preferential intracellular cation, reduces excitability of neurons and neuromuscular transfer of excitement, takes part in many enzymatic processes.

Magnesium is an essential element of bodies and fabrics; a half from total quantity of content of magnesium in an organism collects in a bone tissue.

Magnesium levels in serum:

- between 12 and 17 mg/l (1 - 1,4 ¼Ø¬ó/l or 0,5 - 0,7 mmol/l): point out moderate deficit of magnesium

- it is lower than 12 mg/l (1 ¼Ø¬ó/l or 0,5 mmol/l): point out heavy deficit of magnesium.

Deficit can be:

- primary, owing to congenital anomaly of metabolism (a chronic inborn hypomagnesiemia);
- secondary, owing to:

• inadequate receipt (heavy malnutrition, alcoholism, exclusively parenteral food);

• disturbances of gastrointestinal absorption (chronic diarrhea, gastrointestinal fistula, gipoparatiroidizm);

• excessive losses of magnesium kidneys (heavy polyuria, abuse of diuretics, chronic pyelonephritis, primary hyper aldosteronism, treatment of Cisplatinum).

The pyridoxine (Wb vitamin) participates in many metabolic processes, promotes improvement of absorption of magnesium from a GIT and to its penetration into cells.

Pharmacokinetics. Gastrointestinal absorption of magnesian salts happens partially by the passive mechanism in which solubility of salt plays the defining role. Extent of this absorption does not exceed 50%. In an organism magnesium is distributed generally in intracellular space (about 99%) from which about 2/3 it is distributed in a bone tissue, and a third is in smooth and cross-striped muscular tissue. Removal of magnesium happens to urine, at least 1/3 from the accepted magnesium dose.

The pyridoxine is soaked up in a small intestine. It is metabolized in a liver with formation pharmacological of active metabolites (pyridoxal phosphate and пиридоксаминофосфат). Distribution is preferential in muscles, a liver and TsNS. Gets through a placenta and into mother's milk. It is removed by kidneys.

Indications to use:

Treatment of the confirmed deficit of magnesium in an organism - both isolated, and associated with other scarce states.

Route of administration and doses:

For intake. Contents of a bag should be dissolved completely in a glass of water of room temperature and to drink right after preparation.

Features of use:

At patients with heavy deficit of magnesium use of drug should be begun with its introduction with an intravenous way. It is also shown to patients with malabsorption.

Drug should be used with care at moderate insufficiency of function of kidneys as there is a risk of development of a gipermagniyemiya.

At the accompanying deficit of calcium deficit of magnesium in an organism should be eliminated prior to calcium administration of drugs.

As this drug contains sucrose, it is contraindicated to patients with intolerance of fructose, with a sprue of glucose and a galactose or insufficiency of Sakha-times-isomaltose.

With care apply at a peptic ulcer of a stomach and duodenum, coronary heart disease.

At severe damages of a liver the pyridoxine in high doses can cause deterioration in its function. At use of a pyridoxine in high doses for a long time (several months or in certain cases - years) the touch neuropathy which is followed by the following symptoms can develop: numbness and vestibular disturbances, a tremor of distal departments of extremities and gradually developing touch ataxy (a lack of coordination of movements). These disturbances usually are reversible and take place after cancellation of high doses of vitamin B.

Side effects:

Drug is well transferred.

From digestive tract: seldom - abdominal pains, diarrhea.

Others: skin reactions, allergic reactions.

Interaction with other medicines:

Salts of phosphorus and calcium. These drugs oppress absorption of magnesium from intestines.

Orally appointed tetracyclines. Between intake of tetracyclines and drugs of magnesium it is necessary to observe an interval not less than 2 hours in connection with decrease in absorption of tetracyclines in digestive tract.

Peroral thrombolytic means. At combined use magnesium weakens effect of these medicines.

Levodopa. Activity of a levodopa (if reception of this drug is not combined using inhibitors of a peripheral dopa-decarboxylase) is inhibited by a pyridoxine. It is necessary to avoid any reception of a pyridoxine if along with a levodopa inhibitors of a peripheral dopa-decarboxylase are not appointed.

Hormonal contraceptives. At simultaneous use increase in concentration of a pyridoxine in blood is possible.

Diuretics. At simultaneous use the pyridoxine exponentiates effect of diuretics.

Izonikotingidrazid, Penicillaminum, Cycloserinum. Reduction of efficiency of a pyridoxine at simultaneous use with these drugs is possible.

Phenytoinum, phenobarbital. At simultaneous use reduction of concentration in a blood plasma of Phenytoinum and phenobarbital is possible.

Contraindications:

- sensitivity to drug components.

- A heavy renal failure with clearance of creatinine less than 30 ml/minute.

- Fenilketonuriya.

- Gipermagniyemiya, Wb vitamin hypervitaminosis, myasthenia гравис.

- Atrioventricular block, heavy arterial hypotension.

- Joint reception with a levodopa.

- Children's age till 1 year.

- Diarrhea.

- Intolerance of fructose, a sprue of glucose or a galactose, deficit of invertase-isomaltase (because of the content in sucrose drug).

Overdose:

The peroral overdose of magnesium usually does not lead to toxic reactions if kidneys function normally. However poisoning with magnesium can develop in case of a renal failure.

Toxic effects depend on magnesium level in blood.

Symptoms: falling of arterial pressure, nausea, vomiting, oppression of TsNS, the broken reflexes, changes an ECG, respiratory depression, a coma, a cardiac standstill and respiratory paralysis, an anuretic syndrome.

Treatment: regidratation, artificial diuresis. At a renal failure the hemodialysis or peritoneal dialysis is necessary

Storage conditions:

In the place protected from moisture and light at a temperature not above 25 °C. To store in the place, unavailable to children. Period of validity 1 year.

Issue conditions:

Without recipe

Packaging:

On 3 g of powder in a bag from the combined material. On 10 or 15 bags in a pack from a cardboard together with the application instruction.